Join the Venous Thromboembolism group to help and get support from people like you.
Venous Thromboembolism News
Venous Thromboembolism Risk Higher for Certain Hormonal Contraceptives
THURSDAY, Feb. 13, 2025 – Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical...
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
THURSDAY, Nov. 14, 2024 – For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE),...
Risk for Venous Thromboembolism Up for Those With Sickle Cell Trait
THURSDAY, Sept. 12, 2024 – Individuals with sickle cell trait (SCT) have an increased risk for venous thromboembolism (VTE), according to a study published online Sept. 12 in Blood Advances....
Oversight of DOAC Prescribing Beneficial for A-Fib, VTE Patients
MONDAY, Aug. 5, 2024 – Direct oral anticoagulant (DOAC) prescribing oversight for off-label prescribing is beneficial while patients are prescribed DOAC, according to a study published online July...
Bariatric Surgery Tied to Higher Short-Term Risk for Venous Thromboembolism
THURSDAY, May 9, 2024 – In the short term, bariatric surgery is associated with a greater risk for venous thromboembolism (VTE), but in the long-term, it is associated with lower risk, according to...
FDA Approves Two New Indications for Xarelto (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for X...
FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children
June 21, 2021 – Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a...
FDA Approves Fragmin (dalteparin sodium) as First Anticoagulant for Venous Thromboembolism in Pediatric Patients
May 16, 2019 – The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE)...
FDA Approves New 10 mg Dosing for Xarelto (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
TITUSVILLE, NJ, OCTOBER 30, 2017 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of Xarelto (rivaroxaban) for reducing t...
FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) – Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the U.S. Food and Drug Administration (FDA) has approved Bevyxxa ...
FDA Medwatch Alert: Eliquis (apixaban) 5 mg tablets: Recall One Lot- Bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets
ISSUE: Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and retail...
FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Thursday, August 21, 2014 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug...
Further information
Related condition support groups
Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Pulmonary Embolism